Khemchand R. Surana, Abhijeet G. Parkhe, Eknath D. Ahire, Anuprita R. Pawar, Survarna Khairnar, Sunil K. Mahajan, Dhananjay M. Patil, Deepak D. Sonawane, Sanjay J. Kshirsagar
Khemchand R. Surana1*, Abhijeet G. Parkhe2, Eknath D. Ahire3, Anuprita R. Pawar1, Survarna Khairnar4, Sunil K. Mahajan5, Dhananjay M. Patil6, Deepak D. Sonawane6, Sanjay J. Kshirsagar3,
1Department of Pharmaceutical Chemistry, Shreeshakti Shaikshanik Sanstha, Divine College of Pharmacy, Satana, Nashik.
2Bharati Vidhyapeeth College of Pharmacy, Belapur, Navi Mumbai.
3Department of Pharmaceutics, MET’s, Institute of Pharmacy, BKC, Adgaon, Nashik – 3.
4Department of Pharmacology, Shreeshakti Shaikshanik Sanstha, Divine College of Pharmacy, Satana, Nashik.
5Department of Pharmaceutical Chemistry, MGV’s Pharmacy College, Panchvati, Nashik.
6Department of Pharmaceutics, Shreeshakti Shaikshanik Sanstha, Divine College of Pharmacy, Satana, Nashik.
Volume - 12,
Issue - 1,
Year - 2022
Nociceptive ache signals the frame to capability or real tissue harm. By contrast, neuropathic ache, which ends from damage or harm to the worried system, persists lengthy in spite of everything symptoms and symptoms of the authentic damage have disappeared. This kind of maladaptive ache affords a full-size scientific problem, because it responds poorly or unpredictably to classical analgesics. There is likewise no single, uniformly well-tolerated drug this is reliably helpful. Neuropathic ache withinside the popular populace is expected to have a occurrence ranging among 3% and 17%. Most of the remedies for neuropathic ache have slight efficacy and gift aspect consequences that restriction their use; therefore, different healing strategies are wished for patients. In this article, the contemporary trendy of care treatment, the rising pharmacological strategies until date, and the preclinical research on novel promising healing alternatives could be reviewed.
Cite this article:
Khemchand R. Surana, Abhijeet G. Parkhe, Eknath D. Ahire, Anuprita R. Pawar, Survarna Khairnar, Sunil K. Mahajan, Dhananjay M. Patil, Deepak D. Sonawane, Sanjay J. Kshirsagar. Current Therapeutic Targets for Neuropathic Pain. Asian Journal of Pharmaceutical Research. 2022; 12(1):96-4. doi: 10.52711/2231-5691.2022.00015
Khemchand R. Surana, Abhijeet G. Parkhe, Eknath D. Ahire, Anuprita R. Pawar, Survarna Khairnar, Sunil K. Mahajan, Dhananjay M. Patil, Deepak D. Sonawane, Sanjay J. Kshirsagar. Current Therapeutic Targets for Neuropathic Pain. Asian Journal of Pharmaceutical Research. 2022; 12(1):96-4. doi: 10.52711/2231-5691.2022.00015 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2022-12-1-15
1. Myers, R.R., W.M. Campana, and V.I. Shubayev, The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discovery Today. 2006. 11(1-2): p. 8-20.
2. Chaudhary, S., et al., Rationalized Approach for The Treatment of Neuropathic Pain. Research Journal of Pharmacy and Technology. 2021. 14(5): p. 2887-2895.
3. Purushothaman, P., A. Sha, and T. Vetrichelvan, Formulation development and Evaluation of immediate and sustained release Bilayer Tablets Containing Amitriptyline HCl and Pregabalin for the treatment of Neuropathic Pain. Asian Journal of Pharmacy and Technology. 2017. 7(3): p. 127-136.
4. Brindisi, M., et al., Development and pharmacological characterization of selective blockers of 2-arachidonoyl glycerol degradation with efficacy in rodent models of multiple sclerosis and pain. Journal of Medicinal Chemistry. 2016. 59(6): p. 2612-2632.
5. Akilashree, S. and P.B. Devi, A Study on Neuropathic Pain: Causes, Grading System, Mechanism-A Review. Research Journal of Pharmacy and Technology. 2019. 12(7): p. 3125-3132.
6. Van Hecke, O., et al., Neuropathic pain in the general population: a systematic review of epidemiological studies. PAIN®. 2014. 155(4): p. 654-662.
7. Smith, B.H. and N. Torrance, Epidemiology of neuropathic pain and its impact on quality of life. Current Pain and Headache Reports. 2012. 16(3): p. 191-198.
8. Amanova, E., et al., Quality of Life of Patients with Neurological Conditions and Neuropathic Pain. Research Journal of Pharmacy and Technology. 2018. 11(2): p. 504-508.
9. Starowicz, K. and B. Przewlocka, Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philosophical Transactions of the Royal Society B: Biological Sciences. 2012. 367(1607): p. 3286-3299.
10. Otrubova, K., C. Ezzili, and D.L. Boger, The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH). Bioorganic and Medicinal Chemistry Letters. 2011. 21(16): p. 4674-4685.
11. Basavraj, P. and M. Nitin, Antinociceptive activity of Tulsi Amrit (A Polyherbal Formulation) in selective pain induced models in rats. Research Journal of Pharmacology and Pharmacodynamics. 2017. 9(4): p. 173-177.
12. Blass, B.E., Acyl Sulfonamides NaV1. 7 Blockers Useful for the Treatment of Pain. 2018, ACS Publications.
13. Bista, P. and W.L. Imlach, Pathological mechanisms and therapeutic targets for trigeminal neuropathic pain. Medicines. 2019. 6(3): p. 91.
14. Starowicz, K., N. Malek, and B. Przewlocka, Cannabinoid receptors and pain. Wiley Interdisciplinary Reviews: Membrane Transport and Signaling. 2013. 2(3): p. 121-132.
15. Gangadhar, M., et al., Future directions in the treatment of neuropathic pain: A review on various therapeutic targets. CNS and Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS and Neurological Disorders). 2014. 13(1): p. 63-81.
16. Mackie, K., Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 2006. 46: p. 101-122.
17. Jadhav, G.B., et al., Analgesic and Antiinflammatory Activity of Amarwel extracts on experimentally induce pain and inflammation on animals. Research Journal of Pharmacology and Pharmacodynamics. 2014. 6(2): p. 112-117.
18. Pokkula, S., et al., Ameliorative effect of papain on behavioral and bio-chemical alterations in in-silico and In-vivo models of neuropathic pain in rats. Research Journal of Pharmacy and Technology. 2020. 13(8): p. 3807-3812.
19. Smith, M.T. and A. Muralidharan, Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion on Therapeutic Targets. 2015. 19(1): p. 25-35.
20. Li, J.-X., Imidazoline I2 receptors: An update. Pharmacology and Therapeutics. 2017. 178: p. 48-56.
21. Gilron, I. and A.H. Dickenson, Emerging drugs for neuropathic pain. Expert Opinion on Emerging Drugs. 2014. 19(3): p. 329-341.
22. Noor, S., et al., LFA-1 antagonist (BIRT377) similarly reverses peripheral neuropathic pain in male and female mice with underlying sex divergent peripheral immune proinflammatory phenotypes. Neuroimmunology and Neuroinflammation. 2019. 6.
23. Adamson Barnes, N.S., et al., Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model. British Journal of Pharmacology. 2016. 173(1): p. 77-87.
24. Witkamp, R., Fatty acids, endocannabinoids and inflammation. European Journal of Pharmacology. 2016. 785: p. 96-107.
25. Galibert, M., et al., Substrate-derived triazolo-and azapeptides as inhibitors of cathepsins K and S. European Journal of Medicinal Chemistry. 2018. 144: p. 201-210.
26. Scalvini, L., D. Piomelli, and M. Mor, Monoglyceride lipase: Structure and inhibitors. Chemistry and Physics of Lipids. 2016. 197: p. 13-24.
27. Seierstad, M. and J.G. Breitenbucher, Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. Journal of Medicinal Chemistry. 2008. 51(23): p. 7327-7343.
28. Surana, K., et al., Benzophenone: a ubiquitous scaffold in medicinal chemistry. MedChemComm, 2018. 9(11): p. 1803-1817.
29. Fowler, C.J., Anandamide uptake explained? Trends in Pharmacological Sciences. 2012. 33(4): p. 181-185.
30. Pillarisetti, S. and I. Khanna, A multimodal disease modifying approach to treat neuropathic pain–inhibition of soluble epoxide hydrolase (sEH). Drug Discovery Today. 2015. 20(11): p. 1382-1390.
31. Milo Jr, L.J., et al., Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors. Journal of Medicinal Chemistry. 2011. 54(13): p. 4365-4377.
32. Kim, C.F. and G. Moalem-Taylor, Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. The Journal of Pain. 2011. 12(3): p. 370-383.
33. Posa, L., et al., Targeting melatonin MT2 receptors: A novel pharmacological avenue for inflammatory and neuropathic pain. Current Medicinal Chemistry. 2018. 25(32): p. 3866-3882.
34. Dib-Hajj, S.D., J.A. Black, and S.G. Waxman, Voltage-gated sodium channels: therapeutic targets for pain. Pain Medicine. 2009. 10(7): p. 1260-1269.
35. Ma, R.S.Y., et al., Voltage gated sodium channels as therapeutic targets for chronic pain. Journal of Pain Research. 2019. 12: p. 2709.
36. Sheeba, D. and V.G. Yadav, Complex Regional Pain Syndrome and Its Treatment: An Overview. Research Journal of Pharmacology and Pharmacodynamics. 2012. 4(3): p. 133-143.
37. Mathie, A., Ion channels as novel therapeutic targets in the treatment of pain. Journal of Pharmacy and Pharmacology. 2010. 62(9): p. 1089-1095.
38. Garach, B.D., Postoperative pain after spine surgery: Comparative efficacy of diclofenac and etoricoxib in combination with tramadol and paracetamol at lower doses. Research Journal of Pharmacology and Pharmacodynamics. 2013. 5(1): p. 62-68.